Fox Run Management L.L.C. Has $1.89 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Fox Run Management L.L.C. significantly increased its stake in United Therapeutics by 404%, acquiring an additional 4,913 shares and bringing their total holdings to 6,129 shares valued at approximately $1.89 million.
• Other institutions, including Lord Abbett & CO. LLC and Prudential PLC, also raised their positions in United Therapeutics, indicating a broader institutional interest with over 94% of the stock owned by institutional investors.
• United Therapeutics reported a miss on earnings with an EPS of $6.41 compared to the expected $6.80, despite achieving a year-over-year revenue increase of 11.7%.

Fox Run Management L.L.C. lifted its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 404.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,129 shares of the biotechnology company's stock after buying an additional 4,913 shares during the quarter. Fox Run Management L.L.C.'s holdings in United Therapeutics were worth $1,889,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Dunhill Financial LLC boosted its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new position in United Therapeutics in the 1st quarter valued at approximately $49,000. State of Wyoming acquired a new stake in United Therapeutics during the 4th quarter valued at $62,000. Curat Global LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $63,000. Finally, Natixis acquired a new stake in shares of United Therapeutics during the fourth quarter worth $85,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research reports. Morgan Stanley cut their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a report on Thursday. Wells Fargo & Company cut their price objective on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. UBS Group boosted their target price on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

United Therapeutics Stock Up 0.3%

Shares of NASDAQ:UTHR traded up $1.07 during midday trading on Friday, reaching $313.13. 703,795 shares of the company were exchanged, compared to its average volume of 683,031. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The stock has a fifty day simple moving average of $295.00 and a two-hundred day simple moving average of $308.79. The firm has a market cap of $14.13 billion, a PE ratio of 12.22, a P/E/G ratio of 4.74 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 earnings per share. The firm's quarterly revenue was up 11.7% on a year-over-year basis. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity

In other news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares of the company's stock, valued at $5,613,606.40. This trade represents a 13.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director directly owned 4,883 shares of the company's stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,681 shares of company stock worth $24,618,359. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.